Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from RemeGen Co. Ltd. Class H ( (HK:9995) ) is now available.
RemeGen Co., Ltd. announced that its drug Telitacicept met the primary endpoint in a Phase III clinical trial for primary Sjögren’s syndrome in China. This marks a significant milestone as Telitacicept is the first BLyS/APRIL dual-target fusion protein drug to complete such a study in this field. The trial demonstrated the drug’s efficacy and safety, addressing a significant unmet clinical need in Sjögren’s syndrome treatment. The company plans to submit a Biologics License Application to the National Medical Products Administration of China and present the data at international conferences. Telitacicept has also been recommended by multiple guidelines in China and has received fast track designation from the U.S. FDA for its Sjögren’s syndrome indication.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$19.59 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company focuses on developing innovative biologic drugs, with a particular emphasis on autoimmune diseases and cancer therapies.
Average Trading Volume: 11,660,673
Technical Sentiment Signal: Buy
Current Market Cap: HK$38.89B
See more insights into 9995 stock on TipRanks’ Stock Analysis page.